

# Handelsbanken Hälsovård Tema (A1 NOK)

The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches. The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time. The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

## Performance

03.06.2024

| YTD    | 1 week | 1 mth. | 3 mån | 1 year | 5 years | 10 years |
|--------|--------|--------|-------|--------|---------|----------|
| 14.65% | -0.27% | 0.13%  | 1.96% | 11.38% | 108.54% | 369.03%  |


## Average performance

| Average perf.      | 2 years | 3 years | 5 years | 10 years |
|--------------------|---------|---------|---------|----------|
| Fund <sup>1</sup>  | 18.30%  | 16.58%  | 17.40%  | 17.23%   |
| Index <sup>2</sup> | 14.68%  | 16.32%  | 15.79%  | 15.77%   |


<sup>1</sup> Calculated on the fund's monthly closing price

<sup>2</sup> Benchmark index: Solactive ISS ESG DM Health Care UCITS Index NTR. The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

## Five years performance



## Portfolio



Stocks 98.59%  
Bonds and Cash 1.41%

As of: 30.04.2024



As of: 30.04.2024

The year began strongly for the fund, which rose just over 16% in SEK during Q1.

Eli Lilly, Novo Nordisk and Zealand Pharma continued as the strongest contributors within the diabetes/obesity area. In conjunction with its capital market day at the beginning of March, Novo Nordisk presented positive data on oral amycretin, an obesity drug that results in a weight loss of 13% after just 12 weeks and has very few side effects. Zealand Pharma also presented very strong Phase 2 data on MASH (liver

## Fund manager



### Christopher Sundman

Experience in the fund industry 1987.  
Portfolio Manager since 1 August 2022.

|                             |                     |
|-----------------------------|---------------------|
| Main category               | Equity Fund         |
| Risk                        | 4                   |
| Rate                        | 466.15 (03.06.2024) |
| Reporting Currency          | NOK                 |
| Price/Trade                 | Daily               |
| Total Rating™               | ★★★★★               |
| Minimum investment          | 0 NOK               |
| Monthly savings             | -                   |
| Traded on the Internet      | No                  |
| Management Fee              | 1.5%                |
| Entry charge                | 0%                  |
| Exit charge                 | 0%                  |
| Fund assets                 | 18,336 MSEK         |
| Distribution per fund unit  | -                   |
| Distribution date           | -                   |
| Fund, date of launch        | 01.12.2000          |
| Share class, date of launch | 02.03.2015          |

## Largest holdings

|                              |       |
|------------------------------|-------|
| Eli Lilly and Co             | 9.81% |
| Novo Nordisk A/S Class B     | 9.80% |
| UnitedHealth Group Inc       | 7.01% |
| Merck & Co Inc               | 5.96% |
| Thermo Fisher Scientific Inc | 5.54% |
| AstraZeneca PLC              | 4.49% |
| Johnson & Johnson            | 3.21% |
| AbbVie Inc                   | 3.01% |
| Sanofi SA                    | 2.83% |
| Cencora Inc                  | 2.82% |

fats), in addition to weight loss with its Survodutide drug and the share rose 30%.

On the negative side was Evotec, whose share price fell when the company's CEO resigned unexpectedly due to unreported trades in the company's shares. Our assessment is that the company's operations and positive outlooks have not been affected and that this is more of a short-term uncertainty. Bioarctic also declined on the back of uncertainty about the target of treating 10,000 patients with Leqembi by the end of Q1. However, our outlook is positive, although it may take longer due to a limited capacity for diagnosis.

In general, we are more positive to the sector this year given that interest rates are stabilizing and access to capital for early biotech and medical technology companies is beginning to return. New holdings in the fund include the medical technology company Shockwave Medical, which uses electrical shockwaves to remove calcification in patients with cardiovascular diseases, as well as Immunome, which works with early research within oncology that focuses on ADC drugs.

As of: 26.04.2024

---

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. [Summary of investors' rights](#).

The fund's fact sheet, risk level, fund rules and prospectus are available at [www.handelsbanken.se/funds](http://www.handelsbanken.se/funds). Handelsbanken does not assume liability for any errors in the information.

[www.handelsbanken.se/funds](http://www.handelsbanken.se/funds)

**Handelsbanken**